Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan may spot dangerous heart blockages without extra probes

NCT ID NCT07176585

Diagnosis Sponsor: Insight Lifetech Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested whether a special ultrasound scan (IVUS) of plaque buildup in heart arteries can accurately diagnose reduced blood flow (functional myocardial ischemia). Researchers enrolled 105 adults with coronary artery disease and compared IVUS results to the standard FFR test. The goal was to see if IVUS plaque measurements could reliably identify blockages that need treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could provide a new, less invasive way to diagnose which heart artery blockages are serious enough to need treatment.
What could go wrong
This is a small, single-site study with only 105 participants. The results may not apply to all patients, and the method needs more testing before it can be widely used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

105 people

The number who actually took part.

Started

Sep 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with multivessel coronary artery disease.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Study participants must be at least 18 years of age and younger than 80 years of age, regardless of gender; 2. Stable coronary artery disease, unstable angina, or acute myocardial infarction (AMI ≥ 7 days); 3. Coronary angiography showed primary lesions with a visual stenosis of 30% to 90% in at least two coronary arteries ≥ 2.5 mm in diameter; 4. Willing to participate in the study and able to understand, read, and sign the informed consent form. Exclusion Criteria: 1. STEMI as clinical presentation within 7 days; 2. Chronic Total Occlusion (CTO) as target vessel; 3. Significant contraindication to adenosine administration (e.g., atrioventricular block, severe asthma, etc.); 4. Study participants are currently participating in other drug or device clinical studies and have not achieved the study endpoints; 5. Pregnant or nursing; 6. Other situations considered by the investigator as unsuitable for participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease

Contacts and locations

Locations

  • Fuwai Hospital,Cams & Pumc

    Beijing, Beijing Municipality, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.